877385-86-9

Usage

Uses

Used in Pharmaceutical Industry:
5-Thiazolecarboxaldehyde, 2-cyclopropylis utilized as an intermediate in the synthesis of various pharmaceuticals, contributing to the development of new drugs and therapeutic agents. Its unique structure and reactivity enable the creation of diverse medicinal compounds with potential applications in treating a wide range of diseases and conditions.
Used in Agrochemical Industry:
In the agrochemical sector, 5-Thiazolecarboxaldehyde, 2-cyclopropylis employed as a key intermediate in the production of agrochemicals. Its incorporation into these compounds can enhance their effectiveness in crop protection, pest control, and other agricultural applications, thereby supporting sustainable and efficient farming practices.
Used in Fine Chemicals Industry:
5-Thiazolecarboxaldehyde, 2-cyclopropylis also used as an intermediate in the synthesis of fine chemicals, which are high-purity chemicals used in various applications such as research, diagnostics, and specialty manufacturing. Its versatility and reactivity make it a valuable component in the development of these high-quality products.
Used in Fragrance and Flavor Industry:
5-Thiazolecarboxaldehyde, 2-cyclopropylis employed in the production of fragrances and flavors due to its characteristic odor. Its unique scent profile allows it to be incorporated into a variety of consumer products, enhancing their sensory appeal and providing a distinct olfactory experience.
Used in Organic Synthesis:
As a valuable reagent in organic synthesis, 5-Thiazolecarboxaldehyde, 2-cyclopropylis instrumental in various chemical reactions. Its presence as a building block in the synthesis of complex organic molecules underscores its importance in the development of new materials, compounds, and chemical processes.

Upstream product

• 1159821-56-3 2-cyclopropylthiazole 
• 68-12-2 N,N-dimethyl-formamide 
• 464192-28-7 2-bromo-1,3-thiazole-5-carbaldehyde 
• 411235-57-9 cyclopropylboronic acid 
• 2065-75-0 2-Bromo-malonaldehyde 
• 20295-34-5 cyclopropanecarbothioamide 
• 36437-19-1 2-chloromalonaldehyde 

Downstream Products

• 1620545-75-6 3,10-dibromo-6-(2-cyclopropyl-1,3-thiazol-5-yl)-1-fluoro-6H-indolo[1,2-c][1,3]benzoxazine 
• 1613081-64-3 dimethyl((2S,2’S)-((2S,2’S)-2,2’-(5,5’-((S)-6-(2-cyclopropylthiazol-5-yl)-1-fluoro-6H-benzo[5,6][1,3]oxazino[3,4-a]indole-3,10-diyl)bis(1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3methyl-1oxobutane-2,1-diyl))dicarbamate 

Relevant academic research and scientific papers

THIAZOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS

Provided herein are compounds of Formula (I) and Formula (II) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of tuberculosis.

Compounds for inhibiting HCV (hepatitis C virus), pharmaceutical composition and application of compounds or pharmaceutical composition

The invention discloses compounds for inhibiting HCV (hepatitis C virus), pharmaceutical composition and an application of the compounds or the pharmaceutical composition. The compounds are compoundsshown in formula (I) or a stereoisomer, geometric isomer, a tautomer, an enantiomer, sulfur oxide, nitrogen oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug of the compounds shown in formula (I); the compounds are effective antiviral drugs, especially can be used for inhibiting the function of NS5A protein encoded by the HCV, thereby effectively inhibiting the HCV.The method for preventing and/or treating drugs or diseases associated with the HCV by the compounds or the composition containing the new compounds has good market development prospects.

Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms

We describe the research that led to the discovery of compound 40 (ruzasvir, MK-8408), a pan-genotypic HCV nonstructural protein 5A (NS5A) inhibitor with a "flat" GT1 mutant profile. This NS5A inhibitor contains a unique tetracyclic indole core while maintaining the imidazole-proline-valine Moc motifs of our previous NS5A inhibitors. Compound 40 is currently in early clinical trials and is under evaluation as part of an all-oral DAA regimen for the treatment of chronic HCV infection.

SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS

The present invention refers to novel substituted thiazole and oxazole compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties. The compounds are useful in the treatment or prophylaxis of diseases associated with P2X7 receptor activity in animals, in particular humans.

HETEROCYCLE-SUBSTITUED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES

The present invention relates to novel Heterocycle-Substituted Tetracyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, A', R 2 R 3, R 4 and R are as defined herein. The present i

THIAZOLYL-SUBSTITUED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES

The present invention relates to novel Thiazolyl-Substituted Tetracyclic Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, A', R2R3, R4 and R5 are as defined herein. The present

Convergent, parallel synthesis of a series of β-substituted 1,2,4-oxadiazole butanoic acids as potent and selective α vβ3 receptor antagonists

We describe a series of 1,2,4-oxadiazoles, which are potent antagonists of the integrin αvβ3 and, in addition, show selectivity relative to the other β3 integrin αIIbβ3. In whole cells, the majority o